Clinical Trial

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Study acronym: IMPULSE
Recruiting
View on ClinicalTrials.gov →
Summary
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-25; most recent amendment 2026-04-29.
Status change: Not Yet Recruiting → Recruiting 2026-02-04
Trial Details
NCT Number NCT06905301
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer
Enrollment 240 participants
Start Date 2026-01-23
Primary Completion 2029-12-31 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-05